Aniridia is a devastating ocular disease requiring intensive eye care, social and community support from birth and throughout an individual’s lifetime.

Recent News

© 2019 Aniridia-net.eu – University of Cologne – Webdesign by Effect Group Ltd.

News

Home > News

18 May 2021

Posted at 18:06h in news by
4 Likes

Limbal stem cells, are a type of stem cells located in a protected area or “niche” of the border between the cornea and the sclera (the white of the eye). These cells have special characteristics that make them essential for the maintenance of the corneal transparency and therefore for optimal vision. Limbal stem cells (often abbreviated as LSCs) have high proliferative potential as well as the ability to regenerate the corneal epithelium following any damage caused by eyelids, tears or trauma. Also, these cells prevent the white tissue from migrating on to the surface of the cornea. In this webinar presented by Ruby Shalom-Feuerstein and Daniel Aberdam, we will learn a little more about the characteristics, behavior, and specific needs of limbal stem cells, as well as of...

18 May 2021

Posted at 17:35h in news, training-schools by
4 Likes

COST Association - European Cooperation in Science and Technology through COST Action #18116 @AniridiaNet is glad to host its first e-Training School on Ocular Surface Disease. Don't miss out on this exceptional opportunity to learn first-hand, from a panel of international scientists and clinical researchers, on the workings of ocular surface imaging, lens and prothesis and ocular surface surgery. Register now to attend to this free all-virtual training program hosted by Vito Romano (from the University of Liverpool). https://esaso.online/join/ Find the training school program HERE. ...

09 May 2021

Posted at 19:30h in news by
5 Likes

Aniridia-Net COST Action in association with AniridiaEurope are glad to announce the second in the live webinar series aiming to disseminate knowledge and news about aniridia. Hosted by Daniel Aberdam (Head of Research in INSERM – Paris), this webinar will give the floor to Ruby Shalom Feuerstein (Professor in Technion - Israel Institute of Technology), to bring us insights on the relevance of stem cells for eye functioning. With the title “Eyes open on stem cells dynamics, signature and niche”, this webinar will be live streamed through Aniridia Europe's YouTube Channel and it is recommended for professionals working in the field. Wednesday 26th May 2021 at 18:00 CEST, save the date for this meeting with science and aniridia. ...

18 Apr 2021

Posted at 07:27h in news by
4 Likes

The Deutsche Ophthalmologische Gesellschaft Annual Congress, held entirely online on october 2020, included an aniridia-focused symposium titled:”Congenital Aniridia: new clinical, genetic and molecular insights from patient cohorts in 5 European countries”. Chaired by Nóra Szentmáry (from the University Saarland) and Neil Lagali (from the University of Linkoping), this symposium provided an update of our current and evolving knowledge of the genetic, clinical, micro-morphological, and molecular aspects of AAK. Opening the session, Barbara Käsmann-Kellner (from the University of Saarland) provided a comprehensive explanation of the broad phenotypic spectrum of PAX6 mutations. Continuing with the symposium, Maria Notara (from the University of Cologne), sets forth the specifics of limbal stem cell deficiency in aniridia patients, followed by an exposition of recent translational findings from ocular surface samples by Lorenz Latta (from the University of...

03 Apr 2021

Posted at 19:34h in news by
4 Likes

Last year, the World Society for Paediatric Ophthalmology and Strabismus (WSPOS) dedicated its 14ht webinar entirely to aniridia. With the participation of recognized experts from four different countries, including Neil Lagali (from the University of Linkoping, in Sweden), Dr. David Walton (from Massachusetts General Hospital in USA) and Hannah Scanga (from University of Pittsburgh, in USA),  Dr. Dominique Bremond-Gignac and Dr. Ken K. Nischal guide the discussion through the in’s and out’s of genetic testing, phenotype-genotype variability, AAK, glaucoma and cataract in aniridia patients. The therapeutic potential of Ataluren, a recent drug under trial for aniridia, was also an interesting topic of discussion in this session. If you missed the webinar, you can find the recording in this link: ...